By Laura Christine McCaughey, University of Technology Sydney

Nearly one million people die every year from bacterial infections that cannot be treated with common antibiotics. This is frightening because right now we don’t have any alternatives to these antibiotics.

Antibiotic resistance occurs when bacteria change in a way that prevents the antibiotic from working. Changes in bacteria, known as resistance mechanisms, come in different forms and can be shared between different bacteria, spreading the problem.

Antibiotic resistance risks returning us to an age where even simple cuts and scrapes can become deadly. For a glimpse of what could be commonplace in our future, here are five of the scariest antibiotic resistant bacteria from the last five years.

1. Extensively drug-resistant Salmonella typhi

This highly contagious bacterium causes typhoid fever, a life-threatening infection that affects about 21 million people around the world every year. About 1% of those affected, or 223,000 people, will die.

In November 2016, a strain of Salmonella typhi emerged in Pakistan. It was resistant to five antibiotics, leaving only one oral antibiotic (azithromycin) able to treat it. Since then there have been 858 reported cases of this infection, resulting in four deaths in just one Pakistani province.

Worryingly, this strain of Salmonella typhi had changed from being multidrug-resistant (resistant to at least three classes of antibiotic) to extensively drug-resistant (resistant to all but two classes of antibiotic) in a single step. It achieved this by acquiring a piece of DNA, called a plasmid, which already contained all the new resistance genes it needed.

Even more concerning is that this strain is now only one step away from being untreatable with all available antibiotics by finding another plasmid with the resistance genes for the last two classes of antibiotic that can kill it.

2. Extensively drug-resistant Mycobacterium tuberculosis

Mycobacterium tuberculosis is the world’s leading infectious killer, causing more than 1.7 million deaths every year. One of the reasons this bacteria is so deadly is its ability to hide inside our cells. This means that to treat tuberculosis infection, people are required to take four different antibiotics continuously for six months.

It’s estimated up to 13% of all new tuberculosis cases are multidrug-resistant, with Europe, including Russia, seeing the highest number of these cases. This is alarming, as multidrug-resistant infections require treatment courses that are much longer (generally 18 to 24 months) and use antibiotics that are expensive and can be bad for the kidneys and other organs.

It’s now been found that 6% of these cases are actually extensively drug-resistant (resistant to all but two classes of antibiotic). With a treatment success rate of only 30%, the global spread of extensively drug-resistant tuberculosis to more than 123 countries is extremely concerning.

3. Pandrug-resistant Klebsiella pneumoniae

Klebsiella pneumoniae is a common bacterium found in the skin, intestines and soil. It causes a range of potentially deadly infections in people with compromised immune systems. As this bacterium is particularly prevalent in hospitals, it’s one of the most critical drug-resistant threats to public health.

In 2013 there were 8,000 reports of multidrug-resistant Klebsiella pneumoniae in the United States alone, with a death rate of 50% for people with bloodstream infections.

In 2016 a strain of Klebsiella pneumoniae was identified in the United States that was resistant to all 26 commonly available antibiotics (known as pandrug-resistant). The patient infected by this bacteria died due to a lack of alternative treatments.

This is not an isolated case; other bacteria are also becoming pandrug-resistant.

4. Pandrug-resistant Pseudomonas aeruginosa

Like Klebsiella pneumoniae, Pseudomonas aeruginosa is a commonly found bacterium that causes infections in people with compromised immune systems. Like Klebsiella pneumoniae, it’s particularly prevalent in hospitals.

In the United States, there are an estimated 51,000 health care-associated Pseudomonas aeruginosa infections each year, with around 400 causing death. In the past five years, 29 cases of pandrug-resistant Pseudomonas aeruginosa infection have been reported in hospitals in England.

Pseudomonas aeruginosa infection is also the leading cause of death for people with cystic fibrosis. In 2013, more than 42% of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection were treated with colistin, the “last line of defence” antibiotic. This is because most of these infections were resistant to every other antibiotic available.

5. Extensively drug-resistant Neisseria gonorrhoeae

There are an estimated 78 million global cases of Neisseria gonorrhoeae, which causes gonorrhoea, a sexually transmitted infection affecting men and women. Although usually not deadly, serious and permanent health problems including infertility can result if the disease goes untreated.

Around one-third of all Neisseria gonorrhoeae infections are resistant to at least one antibiotic. More worryingly, a new extensively drug-resistant “super gonorrhoeae”, resistant to all but one antibiotic, has been discovered.

Two of the first reported cases of this superbug were in Australia. This is cause for concern, as extensively drug-resistant Neisseria gonorrhoeae can spread quickly through a population if people have multiple partners. In rare cases, untreated gonorrhoea can enter the bloodstream, causing septic shock and death.

Could future outbreaks be worse?

Yes. Bacteria have the ability to pass antibiotic resistance genes to other bacteria and can develop the resistance themselves. So it’s likely a bacteria resistant to all but one antibiotic will develop resistance to that final one over time.

The good news is we can reduce the likelihood of this happening if we use antibiotics appropriately and invest in the research and development of new antibiotics, vaccines and diagnostic tools.

Laura Christine McCaughey, Research Fellow in Microbiology, University of Technology Sydney

This article was originally published on The Conversation. Read the original article.